{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-021877","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.370077+00:00","generated_at":"2026-05-31T23:42:59.185344+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dyadic enters recombinant albumin partnership with Proliant; $1.5M upfront milestone payments + profit share","bullets":["Dyadic receives $1.5M upfront milestone payment and profit share from Proliant for recombinant albumin license.","First product (recombinant human serum albumin) expected to launch in first half of 2025.","Partnership targets ~$6B serum albumin market for cell culture, vaccine, medical device, diagnostic segments.","Dyadic's COO states agreement demonstrates strategy to commercialize products and generate near-term revenue in Alternative Proteins."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-021877","json":"https://secwatch.observer/filing/0001437749-24-021877.json","markdown":"https://secwatch.observer/filing/0001437749-24-021877.md","text":"https://secwatch.observer/filing/0001437749-24-021877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924021877/0001437749-24-021877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924021877/dyai20240627_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:42:59.185344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}